| Patient | Sun Yat-sen |
|---|---|
| Date of birth | 1968-11-12 |
| Identifiers | MRN HR-ET016-SYN; SSN (made up) 000-16-4183 |
| Document date | 2026-11-01 |
| Author | Wen-Li Huang, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient with a right upper abdominal mass, aching and weight loss: work-up of a liver mass, symptom care, and how he wants to receive results. Concerns: He has had a dull ache under his right ribs, early fullness and weight loss for three months, and can feel a firm lump there himself; As a physician by training he wants to see his images and results himself, to be told plainly, and to be cared for on the same pathway as any other patient; He wants to keep working and traveling for as long as he can. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 2026-05-04 | active | S |
| Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles | Intravenous route | 2026-06-01 | active | S |
| Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles, with hydration | Intravenous route | 2026-06-01 | active | S |
| Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle | Day 1 of each 21-day cycle with chemotherapy, then every 4 weeks alone | Intravenous route | 2026-06-01 | active | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet by mouth every 8 hours as needed for nausea | Oral route | 2026-06-01 | active | S |
| Magnesium oxide 400 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-10-26 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Ultrasound of the abdomen | 2026-05-04 to 2026-05-04 | completed | S |
| Multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis | 2026-05-07 to 2026-05-07 | completed | S |
| MRI of the liver with MRCP | 2026-05-11 to 2026-05-11 | completed | S |
| Ultrasound-guided core biopsy of the liver mass | 2026-05-13 to 2026-05-13 | completed | S |
| Multidisciplinary hepatobiliary tumor board review before staging | 2026-05-20 to 2026-05-20 | completed | S |
| Staging laparoscopy | 2026-05-27 to 2026-05-27 | completed | S |
| Biopsy of peritoneal nodules at staging laparoscopy | 2026-05-27 to 2026-05-27 | completed | S |
| Implanted venous access port placed under the same anesthetic | 2026-05-27 to 2026-05-27 | completed | S |
| Multidisciplinary hepatobiliary tumor board review after staging laparoscopy | 2026-05-29 to 2026-05-29 | completed | S |
| Restaging contrast CT of the chest, abdomen and pelvis after three cycles | 2026-07-30 to 2026-07-30 | completed | S |
| Restaging contrast CT of the chest, abdomen and pelvis after seven cycles | 2026-10-22 to 2026-10-22 | completed | S |
| Advance care planning conversation, about 25 minutes | 2026-09-21 to 2026-09-21 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-09-21 | Influenza vaccine, 2026-2027 season (inactivated) | completed | S |
| 2026-09-21 | COVID-19 vaccine, 2026-2027 formula | completed | S |
| 2026-09-21 | Pneumococcal conjugate vaccine (PCV20), for immunosuppression by chemotherapy | completed | S |
| 2026-10-26 | Recombinant zoster vaccine, first of two doses | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He has had a dull ache under his right ribs, early fullness and weight loss for three months, and can feel a firm lump there himself | active | S |
| As a physician by training he wants to see his images and results himself, to be told plainly, and to be cared for on the same pathway as any other patient | active | S |
| He wants to keep working and traveling for as long as he can | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 3.9 on 2026-09-02; Hemoglobin [Mass/volume] in Blood 10.6 on 2026-09-02; Platelets [#/volume] in Blood by Automated count 162 on 2026-09-02; Sodium [Moles/volume] in Serum or Plasma 137 on 2026-10-26; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.95 on 2026-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 93 on 2026-10-26; Glucose [Mass/volume] in Serum or Plasma 96 on 2026-10-26; Albumin [Mass/volume] in Serum or Plasma 3.7 on 2026-10-26; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 2026-10-26; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 141 on 2026-10-26; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 2026-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 on 2026-10-26; INR in Platelet poor plasma by Coagulation assay 1 on 2026-05-04; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 3.2 on 2026-05-04; Cancer Ag 19-9 [Units/volume] in Serum or Plasma 121 on 2026-10-26; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 8.6 on 2026-05-04; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-09-21; ECOG Performance Status score 1 on 2026-10-26; Neutrophils [#/volume] in Blood by Automated count 1.6 on 2026-09-02; Magnesium [Mass/volume] in Serum or Plasma 1.6 on 2026-10-26; Thyrotropin [Units/volume] in Serum or Plasma 3.1 on 2026-10-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-10-26 [S]
Strengths and supports: Strengths and supports: a clear, analytical mind and his own medical training; a strong sense of purpose in his work; a wide circle of colleagues [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed | R19.01 | S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis. |
| Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed | C23 | S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy. |
| Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed | Z86.19 | S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis. |
| Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectable | active | confirmed | C78.6 | S — Synthetic finding anchored to the peritoneal metastases reported at autopsy. |
| Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolved | resolved | confirmed | J06.9 | S — Synthetic acute illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 7.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 342 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-04 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-04 | Albumin [Mass/volume] in Serum or Plasma | 3.4 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-05-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 2026-05-04 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 212 | U/L | 40-129 U/L | High | S |
| 2026-05-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 10-40 U/L | High | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 7-55 U/L | Normal | S |
| 2026-05-04 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.9-1.1 | Normal | S |
| 2026-05-04 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 3.2 | ng/mL | <=8.3 ng/mL | Normal | S |
| 2026-05-04 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 412 | U/mL | <=35 U/mL | High | S |
| 2026-05-04 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 8.6 | ng/mL | Up to 3.0 ng/mL in non-smokers | High | S |
| 2026-05-04 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-05-04 | ECOG Performance Status score | 1 | {score} | S | ||
| 2026-05-18 | ECOG Performance Status score | 1 | {score} | S | ||
| 2026-06-01 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-01 | Neutrophils [#/volume] in Blood by Automated count | 4.9 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-06-01 | Hemoglobin [Mass/volume] in Blood | 12.2 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-06-01 | Platelets [#/volume] in Blood by Automated count | 318 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-01 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-06-01 | Albumin [Mass/volume] in Serum or Plasma | 3.4 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-06-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 2026-06-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 236 | U/L | 40-129 U/L | High | S |
| 2026-06-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 10-40 U/L | High | S |
| 2026-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 7-55 U/L | Normal | S |
| 2026-06-01 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-06-01 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 498 | U/mL | <=35 U/mL | High | S |
| 2026-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-06-01 | ECOG Performance Status score | 1 | {score} | S | ||
| 2026-08-03 | Leukocytes [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-08-03 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-08-03 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-08-03 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-03 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-03 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 97 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-03 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-03 | Magnesium [Mass/volume] in Serum or Plasma | 1.7 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-08-03 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-08-03 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 2026-08-03 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 158 | U/L | 40-129 U/L | High | S |
| 2026-08-03 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 10-40 U/L | Normal | S |
| 2026-08-03 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
| 2026-08-03 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-08-03 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 168 | U/mL | <=35 U/mL | High | S |
| 2026-08-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-08-03 | ECOG Performance Status score | 1 | {score} | S | ||
| 2026-10-26 | Leukocytes [#/volume] in Blood by Automated count | 4.3 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-26 | Neutrophils [#/volume] in Blood by Automated count | 2.1 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 10.7 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-10-26 | Platelets [#/volume] in Blood by Automated count | 176 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.95 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-26 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 1.7-2.2 mg/dL | Low | S |
| 2026-10-26 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-10-26 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 2026-10-26 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 141 | U/L | 40-129 U/L | High | S |
| 2026-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 10-40 U/L | Normal | S |
| 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 2026-10-26 | Thyrotropin [Units/volume] in Serum or Plasma | 3.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-10-26 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 121 | U/mL | <=35 U/mL | High | S |
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-10-26 | ECOG Performance Status score | 1 | {score} | S | ||
| 2026-09-02 | Leukocytes [#/volume] in Blood by Automated count | 3.9 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-09-02 | Neutrophils [#/volume] in Blood by Automated count | 1.6 | 10*3/uL | 1.8-7.7 10*3/uL | Low | S |
| 2026-09-02 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-09-02 | Platelets [#/volume] in Blood by Automated count | 162 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-04 | Body height | 165 | cm | S |
| 2026-05-04 | Body weight | 61 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 88 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.9 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-18 | Body height | 165 | cm | S |
| 2026-05-18 | Body weight | 60.6 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 86 | /min | S |
| 2026-05-18 | Respiratory rate | 16 | /min | S |
| 2026-05-18 | Body temperature | 36.8 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-01 | Body height | 165 | cm | S |
| 2026-06-01 | Body weight | 60 | kg | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-06-01 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-06-01 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-01 | Heart rate | 84 | /min | S |
| 2026-06-01 | Respiratory rate | 16 | /min | S |
| 2026-06-01 | Body temperature | 36.7 | Cel | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-03 | Body height | 165 | cm | S |
| 2026-08-03 | Body weight | 59.2 | kg | S |
| 2026-08-03 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 2026-08-03 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-08-03 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-03 | Heart rate | 82 | /min | S |
| 2026-08-03 | Respiratory rate | 16 | /min | S |
| 2026-08-03 | Body temperature | 36.6 | Cel | S |
| 2026-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-26 | Body height | 165 | cm | S |
| 2026-10-26 | Body weight | 59.6 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 80 | /min | S |
| 2026-10-26 | Respiratory rate | 16 | /min | S |
| 2026-10-26 | Body temperature | 36.6 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-02 | Body height | 165 | cm | S |
| 2026-09-02 | Body weight | 59 | kg | S |
| 2026-09-02 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 2026-09-02 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-09-02 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-02 | Heart rate | 90 | /min | S |
| 2026-09-02 | Respiratory rate | 16 | /min | S |
| 2026-09-02 | Body temperature | 37.4 | Cel | S |
| 2026-09-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-21 | Body height | 165 | cm | S |
| 2026-09-21 | Body weight | 59.4 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 80 | /min | S |
| 2026-09-21 | Respiratory rate | 16 | /min | S |
| 2026-09-21 | Body temperature | 36.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-05-04 | New patient with a right upper abdominal mass, aching and weight loss: work-up of a liver mass, symptom care, and how he wants to receive results | finished | S |
| 2026-05-18 | Biopsy and imaging results and medical oncology consultation; diagnosis, staging plan, and hepatitis B status | finished | S |
| 2026-06-01 | Staging laparoscopy result and tumor board recommendation; first cycle of chemoimmunotherapy and specialist palliative care | finished | S |
| 2026-08-03 | Before cycle 4: restaging CT, tumor marker, toxicity review, hepatitis B monitoring, and genomic profiling result | finished | S |
| 2026-10-26 | Before cycle 8: restaging CT, toxicity review, low magnesium, and the plan for maintenance durvalumab | finished | S |
| 2026-09-02 | Same-day sick visit for a cold during chemoimmunotherapy | finished | S |
| 2026-09-21 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Work-up of the liver mass: multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis; MRI of the liver with MRCP if CT does not settle the origin; alpha-fetoprotein, CA 19-9 and CEA; hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody; liver function with Child-Pugh and ALBI scoring; and image-guided core biopsy, because a mass in a liver without cirrhosis cannot be diagnosed by imaging alone | completed | GL-AASLD-HCC-2023, GL-NCCN-BIL-2026 | S |
| Medical oncology consultation for a solid liver mass with weight loss: diagnosis, staging, multidisciplinary tumor board review, and treatment | completed | GL-NCCN-BIL-2026, GL-AASLD-HCC-2023 | S |
| Symptom care during the work-up: acetaminophen up to 3,000 mg a day, small frequent meals with a dietitian's advice, weight at every visit, and a same-day call for jaundice, fever, vomiting, dark urine or worse pain; results shared with him in full as they arrive, by one coordinating clinician | completed | GL-NCCN-BIL-2026 | S |
| Staging laparoscopy before any attempt at resection, with biopsy of any peritoneal disease and an implanted port under the same anesthetic; if no metastases, extended cholecystectomy with resection of liver segments IVb and V and portal lymphadenectomy; comprehensive genomic profiling of the biopsy tissue (HER2, mismatch repair and microsatellite status, BRAF, FGFR2, IDH1, NTRK, RET, KRAS, tumor mutational burden) | completed | GL-NCCN-BIL-2026 | S |
| Hepatitis B reactivation monitoring for resolved infection (surface antigen negative, core antibody positive, HBV DNA undetectable): HBV DNA and ALT every 3 months during treatment and for at least 6 to 12 months after, with entecavir started promptly if HBV DNA becomes detectable or surface antigen reappears | completed | GL-ASCO-HBV-2020 | S |
| First-line systemic therapy for stage IVB gallbladder adenocarcinoma: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1 every 21 days for up to 8 cycles, then durvalumab 1,500 mg every 4 weeks until progression or unacceptable toxicity; blood count, creatinine, magnesium and liver tests before each dose; TSH every cycle; CA 19-9 each cycle; CT of the chest, abdomen and pelvis every 2 to 3 months; teaching on immune-related side effects; ondansetron at home | completed | GL-NCCN-BIL-2026, GL-TOPAZ1-2022, GL-ASCO-IRAE-2021 | S |
| Specialist palliative care alongside cancer treatment from the diagnosis of advanced disease: symptoms, nutrition, coping, goals of care, a health care agent, and a family meeting if and when he chooses | completed | GL-ASCO-PALL-2017 | S |
| Magnesium oxide 400 mg by mouth daily for cisplatin-related low magnesium, rechecked with each dose; durvalumab maintenance every 4 weeks after the eighth cycle, with restaging CT every 2 to 3 months | completed | GL-NCCN-BIL-2026, GL-TOPAZ1-2022 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Tissue diagnosis and complete staging within four weeks of the first visit | 2026-06-01 | completed | Biopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeks | S |
| Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1) | 2026-10-26 | completed | Ache 0 to 2 of 10 on acetaminophen as needed; ECOG 1 throughout | S |
| Weight held within 2 kg of the weight at the start of treatment | 2026-10-26 | completed | 60.0 kg at cycle 1 and 59.6 kg at cycle 8 | S |
| Goals of care and a health care agent documented, and revisited as treatment changes | 2026-09-21 | completed | Agent named and goals recorded with palliative care and at the preventive visit | S |
| Complete first-line chemoimmunotherapy without grade 3 or higher toxicity | 2026-10-26 | active | Seven cycles given by the last visit with grade 1 toxicity only; the eighth started that day | S |